先进影像参数提高对IDH突变且无1p19q共缺失的弥漫性低级别胶质瘤亚型的预测:对T2/FLAIR错配征的附加价值
本研究纳入110例弥漫性低级别胶质瘤患者,评估在T2/FLAIR错配征基础上加入ADC和CBV直方图参数对区分IDH突变或无1p/19q共缺失的分子亚型的诊断价值。结果显示联合模型区分IDHmut-Noncodel与其他两组的AUC为0.88(95%CI 0.81-0.96),加入ADC或CBV参数后AUC从0.810提高到0.882,从IDHwt中区分时AUC从0.868提高到0.923。
要点
- T2/FLAIR错配征联合ADC或CBV直方图参数可提高IDHmut-Noncodel亚型的识别。
- 多变量模型区分IDHmut-Noncodel与其他弥漫性低级别胶质瘤的AUC为0.88(95%CI 0.81-0.96)。
- IDHmut-Noncodel型与中间治疗结局相关,识别该亚型可能有助于确定临床方法。
核心结论
- T2/FLAIR错配征联合ADC或CBV直方图参数可提高对IDHmut-Noncodel弥漫性低级别胶质瘤的识别,且易于在临床实践中应用。
研究设计与样本
- 研究纳入110例弥漫性低级别胶质瘤患者,术前接受常规、扩散加权和动态磁敏感对比增强成像。
- 研究人群按分子亚型分为三组:IDH突变且1p/19q共缺失(IDHmut-Codel)、IDH野生型(IDHwt)和IDH突变且无1p/19q共缺失(IDHmut-Noncodel)。
- 评估T2/FLAIR错配征以及ADC和标准化脑血容量(nCBV)直方图参数,构建多变量逻辑回归模型区分IDHmut-Noncodel与IDHmut-Codel及IDHwt,并与单参数AUC比较。
关键影像表现/征象
- 阳性视觉T2/FLAIR错配征和较高的nCBV偏度是区分IDHmut-Noncodel与其他两组的显著变量。
- 较低的ADC10是区分IDHmut-Noncodel与IDHwt组的显著变量。
诊断标准与关键数值
- 阳性视觉T2/FLAIR错配征联合较高nCBV偏度区分IDHmut-Noncodel与其他两组的AUC为0.88(95%CI 0.81-0.96)。
- 较低ADC10区分IDHmut-Noncodel与IDHwt组的AUC为0.75(95%CI 0.62-0.89)。
- T2/FLAIR错配征联合ADC或CBV直方图参数区分IDHmut-Noncodel与其他两组的AUC为0.882,对比单用T2/FLAIR错配征的AUC为0.810。
- T2/FLAIR错配征联合ADC或CBV直方图参数区分IDHmut-Noncodel与IDHwt的AUC为0.923,对比单用T2/FLAIR错配征的AUC为0.868。
临床应用与阅片要点
- 在阅片和报告中,可关注T2/FLAIR错配征阳性并结合ADC或CBV直方图参数,以提高对IDHmut-Noncodel弥漫性低级别胶质瘤的识别。
- 多变量模型区分IDHmut-Noncodel与其他弥漫性低级别胶质瘤的性能显著优于单用T2/FLAIR错配征或任何单一参数。
- IDHmut-Noncodel型与中间治疗结局相关,识别该亚型可能有助于确定临床方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: A combination of T2/FLAIR mismatch sign and advanced imaging parameters may improve the determination of molecular subtypes of diffuse lower-grade glioma. We assessed the diagnostic value of adding the apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) to the T2/FLAIR mismatch sign for differentiation of the IDH mutation or 1p/19q codeletion.
MATERIALS AND METHODS: Preoperative conventional, diffusion-weighted, and dynamic susceptibility contrast imaging were performed on 110 patients with diffuse lower-grade gliomas. The study population was classified into three groups using molecular subtype, namely IDH mutation and 1p/19q codeletion (IDHmut-Codel), IDH wild type (IDHwt) and IDH mutation and no 1p/19q codeletion (IDHmut-Noncodel). T2/FLAIR mismatch sign and the histogram parameters of apparent diffusion coefficient (ADC) and normalised cerebral blood volume (nCBV) values were assessed. A multivariate logistic regression model was constructed to distinguish IDHmut-Noncodel from IDHmut-Codel and IDHwt and from IDHwt, and the performance was compared with that of single parameters using the area under the receiver operating characteristics curve (AUC).
RESULTS: Positive visual T2/FLAIR mismatch sign and higher nCBV skewness were significant variables to distinguish IDHmut-Noncodel from the other two groups (AUC, 0.88; 95% CI, 0.81-0.96). A lower ADC10 was a significant variable for distinguishing IDHmut-Noncodel from the IDHwt group (AUC, 0.75; 95% CI, 0.62-0.89). Adding ADC or CBV histogram parameters to T2/FLAIR mismatch sign improved performance in distinguishing IDHmut-Noncodel from the other two groups (AUC 0.882 vs. AUC 0.810) or from IDHwt (AUC 0.923 vs. AUC 0.868).
CONCLUSIONS: The combination of the T2/FLAIR mismatch sign with ADC or CBV histogram parameters can improve the identification of IDHmut-Noncodel diffuse lower-grade gliomas, which can be easily applied in clinical practice.
KEY POINTS: • The combination of the T2/FLAIR mismatch sign with the ADC or CBV histogram parameters can improve the identification of IDHmut-Noncodel diffuse lower-grade gliomas. • The multivariable model showed a significantly better performance for distinguishing the IDHmut-Noncodel group from other diffuse lower-grade gliomas than the T2/FLAIR mismatch sign alone or any single parameter. • The IDHmut-Noncodel type was associated with intermediate treatment outcomes; therefore, the identification of IDHmut-Noncodel diffuse lower-grade gliomas could be helpful for determining the clinical approach.
引用
- Lee MK, Park JE, Jo Y, et al. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol. 2019. PMID: 31446467. doi:10.1007/s00330-019-06395-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。